FibroGen Financial Statements (FGEN)
|
|
|
|
Report date
|
|
|
28.02.2022 |
27.02.2023 |
26.02.2024 |
17.03.2025 |
16.03.2026 |
|
12.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
235.3 |
140.7 |
46.8 |
29.6 |
6.44 |
|
7.44 |
|
Operating Income, bln rub |
|
|
-288.5 |
-301.0 |
-322.7 |
-150.4 |
-45.9 |
|
-44.8 |
|
EBITDA, bln rub |
? |
|
-333.7 |
-282.8 |
-305.2 |
-142.4 |
-45.9 |
|
-45.5 |
|
Net profit, bln rub |
? |
|
-290.0 |
-293.7 |
-284.2 |
-47.6 |
183.5 |
|
163.6 |
|
|
OCF, bln rub |
? |
|
-82.2 |
-145.9 |
-315.0 |
-138.0 |
-4.77 |
|
-21.4 |
|
CAPEX, bln rub |
? |
|
30.2 |
38.7 |
2.52 |
0.266 |
0.038 |
|
0.022 |
|
FCF, bln rub |
? |
|
-112.4 |
-184.7 |
-317.5 |
-138.3 |
-4.81 |
|
-21.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
2.23 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
74.6 |
421.5 |
365.6 |
164.5 |
51.2 |
|
49.3 |
|
Cost of production, bln rub |
|
|
449.2 |
20.3 |
3.96 |
15.6 |
0.000 |
|
1.35 |
|
R&D, bln rub |
|
|
387.0 |
296.8 |
266.5 |
95.7 |
23.5 |
|
21.9 |
|
Interest expenses, bln rub |
|
|
1.08 |
1.44 |
8.10 |
8.25 |
8.76 |
|
8.62 |
|
|
Assets, bln rub |
|
|
773.8 |
610.1 |
423.5 |
214.5 |
119.6 |
|
109.6 |
|
Net Assets, bln rub |
? |
|
209.1 |
-21.4 |
-204.2 |
-225.6 |
4.48 |
|
-9.29 |
|
Debt, bln rub |
|
|
99.7 |
89.9 |
170.5 |
90.2 |
0.000 |
|
0.000 |
|
Cash, bln rub |
|
|
405.2 |
422.0 |
235.6 |
50.5 |
89.0 |
|
87.2 |
|
Net debt, bln rub |
|
|
-305.5 |
-332.1 |
-65.1 |
39.7 |
-89.0 |
|
-87.2 |
|
|
Ordinary share price, rub |
|
|
352.5 |
|
|
13.2 |
8.78 |
|
9.07 |
|
Number of ordinary shares, mln |
|
|
92.3 |
93.6 |
97.3 |
100.0 |
4.04 |
|
4.05 |
|
|
Market cap, bln rub |
|
|
32 553 |
0 |
0 |
1 325 |
35 |
|
37 |
|
EV, bln rub |
? |
|
32 248 |
-332 |
-65 |
1 364 |
-53 |
|
-51 |
|
Book value, bln rub |
|
|
209 |
-21 |
-204 |
-226 |
4 |
|
-9 |
|
|
EPS, rub |
? |
|
-3.14 |
-3.14 |
-2.92 |
-0.48 |
45.4 |
|
40.4 |
|
FCF/share, rub |
|
|
-1.22 |
-1.97 |
-3.26 |
-1.38 |
-1.19 |
|
-5.29 |
|
BV/share, rub |
|
|
2.26 |
-0.23 |
-2.10 |
-2.26 |
1.11 |
|
-2.30 |
|
|
EBITDA margin, % |
? |
|
-141.8% |
-201.0% |
-652.1% |
-480.8% |
-712.7% |
|
-612.2% |
|
Net margin, % |
? |
|
-123.3% |
-208.7% |
-607.3% |
-160.6% |
2 849% |
|
2 200% |
|
FCF yield, % |
? |
|
-0.35% |
|
|
-10.4% |
-13.6% |
|
-58.3% |
|
ROE, % |
? |
|
-138.7% |
1 369% |
139.2% |
21.1% |
4 099% |
|
-1 761% |
|
ROA, % |
? |
|
-37.5% |
-48.1% |
-67.1% |
-22.2% |
153.4% |
|
149.2% |
|
|
P/E |
? |
|
-112.2 |
0.00 |
0.00 |
-27.8 |
0.19 |
|
0.22 |
|
P/FCF |
|
|
-289.6 |
0.00 |
0.00 |
-9.58 |
-7.38 |
|
-1.72 |
|
P/S |
? |
|
138.3 |
0.00 |
0.00 |
44.7 |
5.51 |
|
4.93 |
|
P/BV |
? |
|
155.6 |
0.00 |
0.00 |
-5.87 |
7.93 |
|
-3.95 |
|
EV/EBITDA |
? |
|
-96.6 |
1.17 |
0.21 |
-9.58 |
1.17 |
|
1.11 |
|
Debt/EBITDA |
|
|
0.92 |
1.17 |
0.21 |
-0.28 |
1.94 |
|
1.92 |
|
|
R&D/CAPEX, % |
|
|
1 282% |
766.1% |
10 579% |
35 974% |
61 887% |
|
99 586% |
|
|
CAPEX/Revenue, % |
|
|
12.8% |
27.5% |
5.38% |
0.90% |
0.59% |
|
0.30% |
|
| FibroGen shareholders |
